Loading clinical trials...
Loading clinical trials...
MB-CART19.1 in Patients With Relapsed/Refractory CD19-positive B Cell Acute Lymphoblastic Leukemia: A Feasibility Study
Conditions
Interventions
MB-CART19.1
Locations
1
Jordan
King Hussein Cancer Center
Amman, Jordan
Start Date
February 1, 2026
Primary Completion Date
January 1, 2029
Completion Date
January 1, 2029
Last Updated
March 25, 2026
NCT07295951
NCT07523555
NCT05735717
NCT07223021
NCT05376111
NCT04065399
Lead Sponsor
King Hussein Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions